John Pablo, MD
Radiation Oncology · Savannah, GANPI 1831237148
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $520 and has fallen 73.4% since, to $138 in 2025.
Across 50 payments — averaging $30.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$206
- Abiomed$170
- Sirtex Medical Inc$158
- Merck$158
- W. L. Gore & Associates, Inc.$144
- Novartis$100
- plus $605 from 17 others
Across 12 payments — averaging $4954.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$59K
What the payments were for
- Food & beverage$1,541100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 2 | $206 |
| Abiomed | 4 | $170 |
| Sirtex Medical Inc | 2 | $158 |
| Merck | 7 | $158 |
| W. L. Gore & Associates, Inc. | 1 | $144 |
| Novartis | 5 | $100 |
| Blue Earth Diagnostics | 4 | $91 |
| Isoray, Inc | 5 | $84 |
| Progenics Pharmaceuticals, Inc. | 3 | $74 |
| Pulmonx Corporation | 1 | $60 |
| Eisai Inc. | 2 | $42 |
| Lilly USA, LLC | 2 | $38 |
| Bayer | 2 | $34 |
| Boston Scientific | 1 | $24 |
| Amgen | 1 | $24 |
| Reflexion Medical, Inc. | 1 | $20 |
| Incyte Corporation | 1 | $20 |
| Brainlab, Inc. | 1 | $18 |
| Bard Peripheral Vascular, Inc. | 1 | $16 |
| Medtronic | 1 | $16 |
| Hologic Inc | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Siemens Medical Solutions USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,541 in reported general payments places this provider in the 75th percentile of 165 radiation oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cevimeline Hcl | 13 | $1,814 |
| Pilocarpine Hcl | 11 | $1,630 |
| Tamsulosin Hcl | 120 | $1,090 |
| Pentoxifylline | 15 | $291 |
| Ciprofloxacin Hcl | 11 | $32 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Savannah
- John MikellSavannah$1K
- Kristin HigginsAtlanta$230K
- Walter CurranAtlanta$83K
- Ian CrockerAtlanta$51K
- Sagar PatelAtlanta$32K
- Hui-Kuo ShuAtlanta$25K
- Wilfred WilliamsAtlanta$15K
- Nancy WiggersAtlanta$11K
- Adam NowlanAtlanta$11K
- Ashesh JaniAtlanta$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.